TY  - JOUR
AU  - Michalickova, Danica
AU  - Kostić-Vučićević, Marija
AU  - Vukašinović-Vesić, Milica
AU  - Stojmenović, Tamara
AU  - Dikić, Nenad
AU  - Anđelković, Marija
AU  - Đorđević, Brižita
AU  - Tanasković, Bojana P.
AU  - Minić, Rajna
PY  - 2017
UR  - http://intor.torlakinstitut.com/handle/123456789/491
AB  - To test the influence of probiotic supplementation on humoral immune response, a double-blind, placebo-controlled trial was conducted. Thirty athletes (24 males and 6 females, females: (V)over dotO(2)max 38.2 +/- 4.9 ml.kg(-1).min(-1), age 23.2 +/- 1.4 years; males: (V)over dotO(2)max 57.5 +/- 9.2 ml.kg(-1).min(-1), age 24.0 +/- 2.4 years, mean +/- SD) were randomized either to the probiotic group (Lactobacillus helveticus Lafti L10, 2 x 10(10) colony-forming units) or to the placebo group. Serum and saliva samples were collected at the baseline and after 14 weeks. Total and specific antibacterial antibody levels of IgM, IgG, and IgA classes were determined for different bacteria in the serum, and in saliva, total and specific antibacterial IgA levels were examined. Total IgM was elevated in both probiotic (18%, 15-20%; mean, 90% confidence interval; p = 0.02) and placebo group (35%, 22-47%; p = 0.02), without observed differences in changes between the groups. No significant changes in IgM levels specific for tested bacteria were found. Total IgG level was constant in both groups. A significant (16%, 22.8 to 35%, p = 0.04) reduction of anti-Enterococcus faecalis IgG was noted in the placebo group, in comparison with the probiotic group. There was a substantial decrease in total IgA level in the placebo group, when measured either in serum (15%, 12-18%, p = 0.04) or in saliva (35%, -1.4 to 53%, p = 0.03). Significantly reduced levels of serum anti-lactic acid bacteria IgA antibodies in the placebo group compared with the probiotic group were detected for Lactobacillus rhamnosus LA68 (24%, 5.8-42%, p = 0.02) and for L. rhamnosus LB64 (15%, 2.7-27%, p = 0.02). Probiotic administration could have beneficial effects on systemic humoral and mucosal immune responses.
PB  - Lippincott Williams & Wilkins, Philadelphia
T2  - Journal of Strength and Conditioning Research
T1  - Lactobacillus helveticus lafti l10 supplementation modulates mucosal and humoral immunity in elite athletes: a randomized, double-blind, placebo-controlled trial
EP  - 70
IS  - 1
SP  - 62
VL  - 31
DO  - 10.1519/JSC.0000000000001456
ER  - 

@article{
author = "Michalickova, Danica and Kostić-Vučićević, Marija and Vukašinović-Vesić, Milica and Stojmenović, Tamara and Dikić, Nenad and Anđelković, Marija and Đorđević, Brižita and Tanasković, Bojana P. and Minić, Rajna",
year = "2017",
abstract = "To test the influence of probiotic supplementation on humoral immune response, a double-blind, placebo-controlled trial was conducted. Thirty athletes (24 males and 6 females, females: (V)over dotO(2)max 38.2 +/- 4.9 ml.kg(-1).min(-1), age 23.2 +/- 1.4 years; males: (V)over dotO(2)max 57.5 +/- 9.2 ml.kg(-1).min(-1), age 24.0 +/- 2.4 years, mean +/- SD) were randomized either to the probiotic group (Lactobacillus helveticus Lafti L10, 2 x 10(10) colony-forming units) or to the placebo group. Serum and saliva samples were collected at the baseline and after 14 weeks. Total and specific antibacterial antibody levels of IgM, IgG, and IgA classes were determined for different bacteria in the serum, and in saliva, total and specific antibacterial IgA levels were examined. Total IgM was elevated in both probiotic (18%, 15-20%; mean, 90% confidence interval; p = 0.02) and placebo group (35%, 22-47%; p = 0.02), without observed differences in changes between the groups. No significant changes in IgM levels specific for tested bacteria were found. Total IgG level was constant in both groups. A significant (16%, 22.8 to 35%, p = 0.04) reduction of anti-Enterococcus faecalis IgG was noted in the placebo group, in comparison with the probiotic group. There was a substantial decrease in total IgA level in the placebo group, when measured either in serum (15%, 12-18%, p = 0.04) or in saliva (35%, -1.4 to 53%, p = 0.03). Significantly reduced levels of serum anti-lactic acid bacteria IgA antibodies in the placebo group compared with the probiotic group were detected for Lactobacillus rhamnosus LA68 (24%, 5.8-42%, p = 0.02) and for L. rhamnosus LB64 (15%, 2.7-27%, p = 0.02). Probiotic administration could have beneficial effects on systemic humoral and mucosal immune responses.",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "Journal of Strength and Conditioning Research",
title = "Lactobacillus helveticus lafti l10 supplementation modulates mucosal and humoral immunity in elite athletes: a randomized, double-blind, placebo-controlled trial",
pages = "70-62",
number = "1",
volume = "31",
doi = "10.1519/JSC.0000000000001456"
}

Michalickova, D., Kostić-Vučićević, M., Vukašinović-Vesić, M., Stojmenović, T., Dikić, N., Anđelković, M., Đorđević, B., Tanasković, B. P.,& Minić, R.. (2017). Lactobacillus helveticus lafti l10 supplementation modulates mucosal and humoral immunity in elite athletes: a randomized, double-blind, placebo-controlled trial. in Journal of Strength and Conditioning Research
Lippincott Williams & Wilkins, Philadelphia., 31(1), 62-70.
https://doi.org/10.1519/JSC.0000000000001456

Michalickova D, Kostić-Vučićević M, Vukašinović-Vesić M, Stojmenović T, Dikić N, Anđelković M, Đorđević B, Tanasković BP, Minić R. Lactobacillus helveticus lafti l10 supplementation modulates mucosal and humoral immunity in elite athletes: a randomized, double-blind, placebo-controlled trial. in Journal of Strength and Conditioning Research. 2017;31(1):62-70.
doi:10.1519/JSC.0000000000001456 .

Michalickova, Danica, Kostić-Vučićević, Marija, Vukašinović-Vesić, Milica, Stojmenović, Tamara, Dikić, Nenad, Anđelković, Marija, Đorđević, Brižita, Tanasković, Bojana P., Minić, Rajna, "Lactobacillus helveticus lafti l10 supplementation modulates mucosal and humoral immunity in elite athletes: a randomized, double-blind, placebo-controlled trial" in Journal of Strength and Conditioning Research, 31, no. 1 (2017):62-70,
https://doi.org/10.1519/JSC.0000000000001456 . .

TY  - CONF
AU  - Marinković, Danica
AU  - Minić, Rajna
AU  - Dikić, Nenad
AU  - Anđelković, Marija
AU  - Vukašinović-Vesić, Milica
AU  - Kostić-Vučićević, Marija
AU  - Stojmenović, Tamara
AU  - Nikolić, Ivan
AU  - Đorđević, Brižita
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2637
UR  - http://intor.torlakinstitut.com/handle/123456789/841
PB  - Lippincott Williams & Wilkins, Philadelphia
C3  - Journal of Clinical Gastroenterology
T1  - The Effect of Lactobacillus Helveticus L10 Supplementation on Respiratory Infections and Mucosal Immunity in Elite Athletes
EP  - S228
IS  - Supplement 2
SP  - S227
VL  - 50
UR  - https://hdl.handle.net/21.15107/rcub_intor_841
ER  - 

@conference{
author = "Marinković, Danica and Minić, Rajna and Dikić, Nenad and Anđelković, Marija and Vukašinović-Vesić, Milica and Kostić-Vučićević, Marija and Stojmenović, Tamara and Nikolić, Ivan and Đorđević, Brižita",
year = "2016",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "Journal of Clinical Gastroenterology",
title = "The Effect of Lactobacillus Helveticus L10 Supplementation on Respiratory Infections and Mucosal Immunity in Elite Athletes",
pages = "S228-S227",
number = "Supplement 2",
volume = "50",
url = "https://hdl.handle.net/21.15107/rcub_intor_841"
}

Marinković, D., Minić, R., Dikić, N., Anđelković, M., Vukašinović-Vesić, M., Kostić-Vučićević, M., Stojmenović, T., Nikolić, I.,& Đorđević, B.. (2016). The Effect of Lactobacillus Helveticus L10 Supplementation on Respiratory Infections and Mucosal Immunity in Elite Athletes. in Journal of Clinical Gastroenterology
Lippincott Williams & Wilkins, Philadelphia., 50(Supplement 2), S227-S228.
https://hdl.handle.net/21.15107/rcub_intor_841

Marinković D, Minić R, Dikić N, Anđelković M, Vukašinović-Vesić M, Kostić-Vučićević M, Stojmenović T, Nikolić I, Đorđević B. The Effect of Lactobacillus Helveticus L10 Supplementation on Respiratory Infections and Mucosal Immunity in Elite Athletes. in Journal of Clinical Gastroenterology. 2016;50(Supplement 2):S227-S228.
https://hdl.handle.net/21.15107/rcub_intor_841 .

Marinković, Danica, Minić, Rajna, Dikić, Nenad, Anđelković, Marija, Vukašinović-Vesić, Milica, Kostić-Vučićević, Marija, Stojmenović, Tamara, Nikolić, Ivan, Đorđević, Brižita, "The Effect of Lactobacillus Helveticus L10 Supplementation on Respiratory Infections and Mucosal Immunity in Elite Athletes" in Journal of Clinical Gastroenterology, 50, no. Supplement 2 (2016):S227-S228,
https://hdl.handle.net/21.15107/rcub_intor_841 .

TY  - JOUR
AU  - Michalickova, Danica
AU  - Minić, Rajna
AU  - Dikić, Nenad
AU  - Anđelković, Marija
AU  - Kostić-Vučićević, Marija
AU  - Stojmenović, Tamara
AU  - Nikolić, Ivan
AU  - Đorđević, Brižita
PY  - 2016
UR  - http://intor.torlakinstitut.com/handle/123456789/607
AB  - A randomized, double-blind, placebo-controlled study was conducted to evaluate if Lactobacillus helveticus Lafti L10 (Lallemand Health Solutions, Montreal, Que., Canada) supplementation during 14 weeks in winter can influence the duration, severity, and incidence of upper respiratory tract illness (URTI), as well as to monitor different immune parameters in the population of elite athletes. Before and after the treatment, cardiopulmonary testing and self-rated state of moods evaluation (by Profile of Mood States questionnaire) were performed and blood samples were collected. Thirty-nine elite athletes were randomized either to the placebo (n = 19) or the probiotic (n = 20) group. The probiotic group received L. helveticus Lafti L10, 2 x 10(10) Colony Forming Units. Lafti L10 significantly shortened the URTI episode duration (7.25 +/- 2.90 vs. 10.64 +/- 4.67 days, p = 0.047) and decreased the number of symptoms in the probiotic group (4.92 +/- 1.96 vs. 6.91 +/- 1.22, p = 0.035). Severity and incidence of URTI did not differ between the treatments. There were no significant changes in leukocyte subpopulation abundance, transforming growth factor-beta serum levels, level of interleukin-10 secreted from peptidoglican stimulated peripheral blood mononuclear cells (PBMCs), interferon-gamma level secreted from concanavalin A-stimulated PBMCs or viability/proliferation of PBMCs upon antigen stimulation. Group effect for CD4+/CD8+ ratio was significant (F-[1,F-37] = 6.99, p = 0.020, eta(2) = 0.350); this difference was not significant at baseline, but was evident after 14 weeks (p = 0.02). A significant interaction effect was noted for self-rated sense of vigor (F-[1,F-37] = 11.76, p = 0.009, eta(2) = 0.595). Self-rated sense of vigor increased in the probiotic group (18.5 +/- 4.1 vs. 21.0 +/- 2.6, p = 0.012). Probiotic strain Lafti L10 can be a beneficial nutritional supplement for the reduction of URTI length in elite athletes.
PB  - Canadian Science Publishing, Ottawa
T2  - Applied Physiology Nutrition and Metabolism
T1  - Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial
EP  - 789
IS  - 7
SP  - 782
VL  - 41
DO  - 10.1139/apnm-2015-0541
ER  - 

@article{
author = "Michalickova, Danica and Minić, Rajna and Dikić, Nenad and Anđelković, Marija and Kostić-Vučićević, Marija and Stojmenović, Tamara and Nikolić, Ivan and Đorđević, Brižita",
year = "2016",
abstract = "A randomized, double-blind, placebo-controlled study was conducted to evaluate if Lactobacillus helveticus Lafti L10 (Lallemand Health Solutions, Montreal, Que., Canada) supplementation during 14 weeks in winter can influence the duration, severity, and incidence of upper respiratory tract illness (URTI), as well as to monitor different immune parameters in the population of elite athletes. Before and after the treatment, cardiopulmonary testing and self-rated state of moods evaluation (by Profile of Mood States questionnaire) were performed and blood samples were collected. Thirty-nine elite athletes were randomized either to the placebo (n = 19) or the probiotic (n = 20) group. The probiotic group received L. helveticus Lafti L10, 2 x 10(10) Colony Forming Units. Lafti L10 significantly shortened the URTI episode duration (7.25 +/- 2.90 vs. 10.64 +/- 4.67 days, p = 0.047) and decreased the number of symptoms in the probiotic group (4.92 +/- 1.96 vs. 6.91 +/- 1.22, p = 0.035). Severity and incidence of URTI did not differ between the treatments. There were no significant changes in leukocyte subpopulation abundance, transforming growth factor-beta serum levels, level of interleukin-10 secreted from peptidoglican stimulated peripheral blood mononuclear cells (PBMCs), interferon-gamma level secreted from concanavalin A-stimulated PBMCs or viability/proliferation of PBMCs upon antigen stimulation. Group effect for CD4+/CD8+ ratio was significant (F-[1,F-37] = 6.99, p = 0.020, eta(2) = 0.350); this difference was not significant at baseline, but was evident after 14 weeks (p = 0.02). A significant interaction effect was noted for self-rated sense of vigor (F-[1,F-37] = 11.76, p = 0.009, eta(2) = 0.595). Self-rated sense of vigor increased in the probiotic group (18.5 +/- 4.1 vs. 21.0 +/- 2.6, p = 0.012). Probiotic strain Lafti L10 can be a beneficial nutritional supplement for the reduction of URTI length in elite athletes.",
publisher = "Canadian Science Publishing, Ottawa",
journal = "Applied Physiology Nutrition and Metabolism",
title = "Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial",
pages = "789-782",
number = "7",
volume = "41",
doi = "10.1139/apnm-2015-0541"
}

Michalickova, D., Minić, R., Dikić, N., Anđelković, M., Kostić-Vučićević, M., Stojmenović, T., Nikolić, I.,& Đorđević, B.. (2016). Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial. in Applied Physiology Nutrition and Metabolism
Canadian Science Publishing, Ottawa., 41(7), 782-789.
https://doi.org/10.1139/apnm-2015-0541

Michalickova D, Minić R, Dikić N, Anđelković M, Kostić-Vučićević M, Stojmenović T, Nikolić I, Đorđević B. Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial. in Applied Physiology Nutrition and Metabolism. 2016;41(7):782-789.
doi:10.1139/apnm-2015-0541 .

Michalickova, Danica, Minić, Rajna, Dikić, Nenad, Anđelković, Marija, Kostić-Vučićević, Marija, Stojmenović, Tamara, Nikolić, Ivan, Đorđević, Brižita, "Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial" in Applied Physiology Nutrition and Metabolism, 41, no. 7 (2016):782-789,
https://doi.org/10.1139/apnm-2015-0541 . .

TY  - JOUR
AU  - Michalickova, Danica
AU  - Minić, Rajna
AU  - Dikić, Nenad
AU  - Anđelković, Marija
AU  - Kostić-Vučićević, Marija
AU  - Stojmenović, Tamara
AU  - Nikolić, Ivan
AU  - Đorđević, Brižita
PY  - 2016
UR  - http://intor.torlakinstitut.com/handle/123456789/476
AB  - A randomized, double-blind, placebo-controlled study was conducted to evaluate if Lactobacillus helveticus Lafti L10 (Lallemand Health Solutions, Montreal, Que., Canada) supplementation during 14 weeks in winter can influence the duration, severity, and incidence of upper respiratory tract illness (URTI), as well as to monitor different immune parameters in the population of elite athletes. Before and after the treatment, cardiopulmonary testing and self-rated state of moods evaluation (by Profile of Mood States questionnaire) were performed and blood samples were collected. Thirty-nine elite athletes were randomized either to the placebo (n = 19) or the probiotic (n = 20) group. The probiotic group received L. helveticus Lafti L10, 2 x 10(10) Colony Forming Units. Lafti L10 significantly shortened the URTI episode duration (7.25 +/- 2.90 vs. 10.64 +/- 4.67 days, p = 0.047) and decreased the number of symptoms in the probiotic group (4.92 +/- 1.96 vs. 6.91 +/- 1.22, p = 0.035). Severity and incidence of URTI did not differ between the treatments. There were no significant changes in leukocyte subpopulation abundance, transforming growth factor-beta serum levels, level of interleukin-10 secreted from peptidoglican stimulated peripheral blood mononuclear cells (PBMCs), interferon-gamma level secreted from concanavalin A-stimulated PBMCs or viability/proliferation of PBMCs upon antigen stimulation. Group effect for CD4+/CD8+ ratio was significant (F-[1,F-37] = 6.99, p = 0.020, eta(2) = 0.350); this difference was not significant at baseline, but was evident after 14 weeks (p = 0.02). A significant interaction effect was noted for self-rated sense of vigor (F-[1,F-37] = 11.76, p = 0.009, eta(2) = 0.595). Self-rated sense of vigor increased in the probiotic group (18.5 +/- 4.1 vs. 21.0 +/- 2.6, p = 0.012). Probiotic strain Lafti L10 can be a beneficial nutritional supplement for the reduction of URTI length in elite athletes.
PB  - Canadian Science Publishing, Ottawa
T2  - Applied Physiology Nutrition and Metabolism
T1  - Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial
EP  - 789
IS  - 7
SP  - 782
VL  - 41
DO  - 10.1139/apnm-2015-0541
ER  - 

@article{
author = "Michalickova, Danica and Minić, Rajna and Dikić, Nenad and Anđelković, Marija and Kostić-Vučićević, Marija and Stojmenović, Tamara and Nikolić, Ivan and Đorđević, Brižita",
year = "2016",
abstract = "A randomized, double-blind, placebo-controlled study was conducted to evaluate if Lactobacillus helveticus Lafti L10 (Lallemand Health Solutions, Montreal, Que., Canada) supplementation during 14 weeks in winter can influence the duration, severity, and incidence of upper respiratory tract illness (URTI), as well as to monitor different immune parameters in the population of elite athletes. Before and after the treatment, cardiopulmonary testing and self-rated state of moods evaluation (by Profile of Mood States questionnaire) were performed and blood samples were collected. Thirty-nine elite athletes were randomized either to the placebo (n = 19) or the probiotic (n = 20) group. The probiotic group received L. helveticus Lafti L10, 2 x 10(10) Colony Forming Units. Lafti L10 significantly shortened the URTI episode duration (7.25 +/- 2.90 vs. 10.64 +/- 4.67 days, p = 0.047) and decreased the number of symptoms in the probiotic group (4.92 +/- 1.96 vs. 6.91 +/- 1.22, p = 0.035). Severity and incidence of URTI did not differ between the treatments. There were no significant changes in leukocyte subpopulation abundance, transforming growth factor-beta serum levels, level of interleukin-10 secreted from peptidoglican stimulated peripheral blood mononuclear cells (PBMCs), interferon-gamma level secreted from concanavalin A-stimulated PBMCs or viability/proliferation of PBMCs upon antigen stimulation. Group effect for CD4+/CD8+ ratio was significant (F-[1,F-37] = 6.99, p = 0.020, eta(2) = 0.350); this difference was not significant at baseline, but was evident after 14 weeks (p = 0.02). A significant interaction effect was noted for self-rated sense of vigor (F-[1,F-37] = 11.76, p = 0.009, eta(2) = 0.595). Self-rated sense of vigor increased in the probiotic group (18.5 +/- 4.1 vs. 21.0 +/- 2.6, p = 0.012). Probiotic strain Lafti L10 can be a beneficial nutritional supplement for the reduction of URTI length in elite athletes.",
publisher = "Canadian Science Publishing, Ottawa",
journal = "Applied Physiology Nutrition and Metabolism",
title = "Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial",
pages = "789-782",
number = "7",
volume = "41",
doi = "10.1139/apnm-2015-0541"
}

Michalickova, D., Minić, R., Dikić, N., Anđelković, M., Kostić-Vučićević, M., Stojmenović, T., Nikolić, I.,& Đorđević, B.. (2016). Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial. in Applied Physiology Nutrition and Metabolism
Canadian Science Publishing, Ottawa., 41(7), 782-789.
https://doi.org/10.1139/apnm-2015-0541

Michalickova D, Minić R, Dikić N, Anđelković M, Kostić-Vučićević M, Stojmenović T, Nikolić I, Đorđević B. Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial. in Applied Physiology Nutrition and Metabolism. 2016;41(7):782-789.
doi:10.1139/apnm-2015-0541 .

Michalickova, Danica, Minić, Rajna, Dikić, Nenad, Anđelković, Marija, Kostić-Vučićević, Marija, Stojmenović, Tamara, Nikolić, Ivan, Đorđević, Brižita, "Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial" in Applied Physiology Nutrition and Metabolism, 41, no. 7 (2016):782-789,
https://doi.org/10.1139/apnm-2015-0541 . .